TACSTD2 and pancreatic neoplasm: Another probe, 68Ga-NOTA-RTD01, featuring improved pharmacokinetics targeting Trop2, was further developed and demonstrated advantageous diagnostic capabilities in preclinical pancreatic cancer models 95.